Cyclosporine and tacrolimus cause significant renal magnesium wasting via inhibition of the TRPM6 magnesium channel in renal tubules. Hypomagnesemia is nearly universal in transplant patients — occurring in 40–75% and associated with rejection risk, seizures, and neurotoxicity.
Navaneethan et al. (Am J Transplant, 2006) — 40–75% of transplant patients develop hypomagnesemia on calcineurin inhibitors. Magnesium deficiency correlates with increased tacrolimus nephrotoxicity. TRPM6 inhibition mechanism confirmed.
Muscle cramps, tremor (amplifying tacrolimus neurotoxicity), seizures, cardiac arrhythmia, worsening nephrotoxicity
Magnesium glycinate 300–600mg daily. Monitor serum magnesium monthly — this is one of the most important monitoring parameters in transplant medicine. IV magnesium may be needed acutely.
View on Fullscript: Thorne Magnesium BisglycinateDiscuss with your physician before adjusting supplementation. This is educational content, not medical advice.
Cyclosporine directly inhibits mitochondrial function and CoQ10 synthesis. This contributes to cyclosporine-induced nephrotoxicity and cardiomyopathy — both of which are mediated partly by mitochondrial oxidative stress.
Bertelli et al. (Drugs Exp Clin Res, 1994) — CoQ10 supplementation significantly reduced cyclosporine-induced cardiomyopathy in transplant patients. Morisco et al. confirmed renal protective effects.
Nephrotoxicity, cardiomyopathy, hypertension, fatigue
Ubiquinol 200–300mg daily. Important note: CoQ10 can minimally affect cyclosporine blood levels — monitor drug levels when initiating.
View on Fullscript: Life Extension Super Ubiquinol CoQ10Discuss with your physician before adjusting supplementation. This is educational content, not medical advice.
Corticosteroids (often co-administered with immunosuppressants) impair Vitamin D activation. Tacrolimus and cyclosporine independently impair renal 1-alpha hydroxylase, reducing conversion of 25-OH-D to active 1,25-OH-D. Transplant patients are also frequently indoors and sun-avoidant.
Stein et al. (Transplantation, 2011) — 80%+ of organ transplant patients are Vitamin D deficient. D3 deficiency post-transplant is associated with increased rejection rates and bone loss.
Osteoporosis (severe — 5–8% bone loss in first year post-transplant), fractures, immune dysregulation, muscle weakness
Vitamin D3 2,000–5,000 IU + K2 daily. Test 25(OH)D quarterly. Active D3 (calcitriol) may be needed if renal conversion is impaired — requires prescriber.
View on Fullscript: Thorne Vitamin D/K2 LiquidDiscuss with your physician before adjusting supplementation. This is educational content, not medical advice.
Taking Immunosuppressants? Build Your Replenishment Stack.
Our clinical intake tool accounts for your medications, health goals, and risk factors — and outputs a personalized supplement protocol rated against published clinical trials.
Open the Full Tool Suite